| Differentiation of beta-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles. | |
| | |
MedLine Citation:
|
PMID: 1361175 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To evaluate the differential effects of beta-blockers on serum lipids and apolipoproteins in normolipidaemic and dyslipidaemic hypertensives, 330 patients with mild to moderate essential hypertension were studied 1 month after placebo therapy and 6 months after monotherapy with propranolol (n = 53), atenolol (n = 66), metoprolol (n = 58), pindolol (n = 53), or celiprolol (n = 100). Serum total cholesterol, triglycerides, high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), and apolipoproteins (Apo) A1 and B were measured at baseline and study end. A total of 136 (41.2%) patients were considered normolipidaemic (pretreatment LDL-C < 160 mg.dl-1) and 194 (58.8%) were considered dyslipidaemic (LDL-C > 160 mg.dl-1). Changes in total cholesterol differed between normolipidaemics and dyslipidaemics with propranolol (+13% in normolipidaemics vs -0.5% in dyslipidaemics, P < 0.001), atenolol (+7% vs -2%, P = 0.01), metoprolol (+9% vs -4%, P0.0006), pindolol (+8% vs -9%, P < 0.001), and celiprolol (-1% vs -13%, P = 0.002). HDL-C differed less, with propranolol (-18% vs -13%), atenolol (-6% vs -2%), metoprolol (-2% vs -6%), pindolol (+4% vs +1%), and celiprolol (+9% vs +4%); none of these changes between normolipidaemic and dyslipidaemic patients were statistically significant. LDL-C changes differed the most, with propranolol (+35% vs -1%, P < 0.0001), atenolol (+15% vs -4%, P = 0.001), metoprolol (+12% vs -6%, P = 0.004), pindolol (+12% vs -13%, P < 0.0001), and celiprolol (+3% vs -16%, P = 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
G P Vyssoulis; E A Karpanou; C E Pitsavos; J N Skoumas; A A Paleologos; P K Toutouzas |
Related Documents
:
|
8044345 - Free cholesterol concentrations in the high-density lipoprotein subfraction-3 as a risk... 1201145 - Long-term effects of colestipol (u-26,597 a) on plasma lipids in familial type ii hyper... 12090905 - High density-lipoprotein subfractions of patients using cardio-selective beta-blockers. 12672915 - Men classified as hypo- or hyperresponders to dietary cholesterol feeding exhibit diffe... 1415485 - Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits. 22818725 - Daily apple versus dried plum: impact on cardiovascular disease risk factors in postmen... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: European heart journal Volume: 13 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1992 Nov |
Date Detail:
|
Created Date: 1993-01-15 Completed Date: 1993-01-15 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1506-13 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, University of Athens, Hippokration General Hospital, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
adverse effects*,
therapeutic use* Apolipoproteins / blood, drug effects* Cholesterol / blood Female Humans Hypertension / blood*, drug therapy* Lipoproteins / blood, drug effects* Male Middle Aged Risk Factors Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Apolipoproteins; 0/Lipoproteins; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with pr...
Next Document: [A novel function of tetrahydrobiopterin].